|
Documentation and Testing | Impact
of Decentralization | J&J's
Response to SOX | About
the Speaker
Johnson & Johnson Executive Discusses
the Impact of Section 404 of Sarbanes-Oxley
Ronald
G. Fulop gave accountancy students a corporate perspective on the Sarbanes-Oxley
Act (SOX) last month. Fulop is vice president for internal audit, corporate
staff, for Johnson & Johnson (J&J)
and his auditing group is responsible for overseeing the internal financial
controls of over 350 J&J entities worldwide. Fulop's talk covered
some pressing challenges within his company because of SOX, the methods
Johnson & Johnson implemented in response to the 2002 legislation,
and a few personal observations about the act.
Documentation and Testing
At September's
Lyceum
lecture, Fulop talked of the challenge companies face when trying
to adhere to the most important element of Section 404 of Sarbanes-Oxley,
which requires a company CEO and CFO to sign off on underlying internal
controls. It is a challenge he confronts with each of J&J's companies.
"We have somewhere between 350-400 entities worldwide. Each year
my internal audit group audits somewhere between 100-150 entities, but
we don't get to every entity every year. So over time, we look at the
controls, which include the maintenance of records that accurately reflect
the transactions, among other elements. Section 404 requires that we ensure
the existence of those controls and also that we document them. Well,
among the things companies like to do least is document."
Fulop
and his team spend a great deal of time and effort testing and documenting
the controls of companies and ensuring that they adhere to the regulations
of the Committee of Sponsoring Organizations (COSO). Fulop noted that
the inability to audit every entity annually, and the compensatory work
that must be done for companies that may not test or document their internal
controls, can contribute to a number of "gaps and misses" within
the documentation.
Impact of Decentralization
Fulop
illustrated J&J's massiveness with some staggering numbers. Along
with the production of baby shampoo and Neutrogena, J&J produces medical
devices such as sutures and staples, the pain relievers Tylenol and Motrin,
and Splenda, a no-calorie sweetener. The New Brunswick-based company is
the 3rd largest pharmaceutical company in the world, employs more than
110,000 people, maintains over 200 operating companies, sells its products
in 175 countries, and counts its total assets in the area of $48 billion.
Because
of its market diversity and size, J&J is a decentralized organization.
Fulop says this decentralization is welcomed, "The local management
knows the marketplace and its customer better than people at corporate
headquarters." But due to J&J's decentralization, Section 404
presents the corporation with challenges in the area of information technology.
"This means we had to comply with the documentation and testing at
all those entities around the world. We got hit heavy because our multiple
planning systems meant we must comply with documentation and testing many
times versus one time with a centralized company that has just one system."
J & J's Response to SOX
The 2002
Sarbanes-Oxley legislation was accompanied by an aggressive reform of
J&J's auditing system. The corporation decided to extend the 404 requirements
to every company within its organization. Fulop cited the adjustments
that were made to each company's auditing practices, "We utilized
the COSO framework: mandated that operating companies assess their controls,
document, and test. Internal audit would provide the tools, train the
companies in what they should do, and provide them advice and counsel."
Fulop
sent roughly 80% of the staff in the internal audit department all over
the world to help. "That was probably one of the few times people
were glad to see internal auditors." After the companies completed
the documentation and testing, the internal audit group evaluated how
well each did. In addition, each company was given an internal control
handbook and a joint assessment questionnaire.
Fulop
looks at SOX positively and believes it already has led to formalization
of many of the controls already in place at J&J. He believes that
the act has drawn the departments within the organization closer, citing
his close interaction with the law department to properly facilitate the
adoption of Section 404 by the corporation's 200 companies. But nonetheless,
there have been costs. With approximately 70-75% of his department working
on Sarbanes-Oxley, roughly 800,000 hours and $40 million have been allocated
annually to make sure that Johnson & Johnson is adhering to SOX regulations.
About the Speaker
A graduate
of the Wharton School of the University of Pennsylvania, Fulop was appointed
to his current position in October 1998. He was vice president for finance
and information management at ETHICON Inc. for thirteen years. He resides
in Neshanic Station, New Jersey, with his wife and three daughters. He
is involved with several charitable organizations, including board of
director positions with the American Red Cross of Somerset County and
Special Olympics of New Jersey.
--Michael
Romain
October 2004
|